Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

620 ARTÍCULOS , VIENDO DEL 31 AL 45

Recent Progress in the Drug Development for the Treatment of Alzheimer's Disease Especially on Inhibition of Amyloid-peptide Aggregation

Liu Y, Cong L, Han C, Li B, Dai R.

Mini Rev Med Chem. 2021;21(8):969-990. doi: 10.2174/1389557520666201127104539.

Current Quest in Natural Bioactive Compounds for Alzheimer's Disease: Multi-Targeted-Designed-Ligand Based Approach with Preclinical and Clinical Based Evidence

Iqubal A, Rahman SO, Ahmed M, Bansal P, Haider MR, Iqubal MK, Najmi AK, Pottoo FH, Haque SE.

Curr Drug Targets. 2021;22(6):685-720. doi: 10.2174/1389450121999201209201004.

The Therapeutic Potential of Purinergic Receptors in Alzheimer's Disease and Promising Therapeutic Modulators

Pan L, Ma Y, Li Y, Wu H, Huang R, Cai Z, Wu X.

Mini Rev Med Chem. 2021;21(11):1288-1302. doi: 10.2174/1389557520999201209211610.

Safety and Efficacy of Lemborexant in Patients With Irregular Sleep-Wake Rhythm Disorder and Alzheimer's Disease Dementia: Results From a Phase 2 Randomized Clinical Trial

Moline M, Thein S, Bsharat M, Rabbee N, Kemethofer-Waliczky M, Filippov G, Kubota N, Dhadda S.

J Prev Alzheimers Dis. 2021;8(1):7-18. doi: 10.14283/jpad.2020.69.

Rapid drug access and scientific rigour: a delicate balance

The Lancet Neurology.

Lancet Neurol. 2021 Jan;20(1):1. doi: 10.1016/S1474-4422(20)30452-X.

APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches

Serrano-Pozo A, Das S, Hyman BT.

Lancet Neurol. 2021 Jan;20(1):68-80. doi: 10.1016/S1474-4422(20)30412-9.

First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M(1) -receptor partial agonist for the treatment of dementias

Bakker C, Tasker T, Liptrot J, Hart EP, Klaassen ES, Prins S, van der Doef TF, Brown GA, Brown A, Congreve M, Weir M, Marshall FH, Cross DM, Groeneveld GJ, Nathan PJ.

Br J Clin Pharmacol. 2021 Jul;87(7):2945-2955. doi: 10.1111/bcp.14710. Epub 2021 Feb 5.

Potential Epigenetic Targets for Combating Alzheimer's Disease

Pandey D, Pal T, Sharma A, Flora S.

Mini Rev Med Chem. 2021;21(12):1527-1540. doi: 10.2174/1389557521999201228191427.

Therapeutic Properties of Several Chemical Compounds of Salvia officinalis L. in Alzheimer's Disease

Uță G, Manolescu DȘ, Avram S.

Mini Rev Med Chem. 2021;21(12):1421-1430. doi: 10.2174/1389557521999201230200209.

Recent Advances in Nanotechnology-Based Drug Delivery Approaches for Alzheimer disease

Kaur I, Kumar A, Behl T, Setia D.

Curr Drug Targets. 2021;22(12):1404-1423. doi: 10.2174/1389450122999210104205018.

Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimer's disease

Yu W, Jin H, Huang Y.

Clin Sci (Lond). 2021 Jan 15;135(1):109-126. doi: 10.1042/CS20200844.

Acetylcholinesterase inhibitors for the treatment of Alzheimer's disease - a patent review (2016-present)

Bortolami M, Rocco D, Messore A, Di Santo R, Costi R, Madia VN, Scipione L, Pandolfi F.

Expert Opin Ther Pat. 2021 May;31(5):399-420. doi: 10.1080/13543776.2021.1874344. Epub 2021 Jan 14.

Nutraceutical based SIRT3 activators as therapeutic targets in Alzheimer's disease

Govindarajulu M, Ramesh S, Neel L, Fabbrini M, Buabeid M, Fujihashi A, Dwyer D, Lynd T, Shah K, Mohanakumar KP, Smith F, Moore T, Dhanasekaran M.

Neurochem Int. 2021 Mar;144:104958. doi: 10.1016/j.neuint.2021.104958. Epub 2021 Jan 12.

Probing Mechanisms and Therapeutic Potential of γ-Secretase in Alzheimer's Disease

Wolfe MS.

Molecules. 2021 Jan 13;26(2):388. doi: 10.3390/molecules26020388.

β-lactam antibiotics to tame down molecular pathways of Alzheimer's disease

Kumari S, Deshmukh R.

Eur J Pharmacol. 2021 Mar 15;895:173877. doi: 10.1016/j.ejphar.2021.173877. Epub 2021 Jan 14.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias